Nicotiana glauca: In Vitro Production of Pyridine Alkaloids and Other Secondary Metabolites

Author(s):  
K. D. Green ◽  
N. H. Thomas
2021 ◽  
Vol 8 (02) ◽  
pp. e62-e68
Author(s):  
Jeeta Sarkar ◽  
Nirmalya Banerjee

AbstractSteroid alkaloid solasodine is a nitrogen analogue of diosgenin and has great importance in the production of steroidal medicines. Solanum erianthum D. Don (Solanaceae) is a good source of solasodine. The aim of this study was to evaluate the effect of different cytokinins on the production of secondary metabolites, especially solasodine in the in vitro culture of S. erianthum. For solasodine estimation, field-grown plant parts and in vitro tissues were extracted thrice and subjected to high-performance liquid Chromatography. Quantitative analysis of different secondary metabolites showed that the amount was higher in the in vitro regenerated plantlets compared to callus and field-grown plants. The present study critically evaluates the effect of the type of cytokinin used in the culture medium on solasodine accumulation in regenerated plants. The highest solasodine content (46.78±3.23 mg g-1) was recorded in leaf extracts of the in vitro grown plantlets in the presence of 6-γ,γ-dimethylallylamino purine in the culture medium and the content was 3.8-fold higher compared to the mother plant.


Author(s):  
Ravi Shankar Singh ◽  
Tirthartha Chattopadhyay ◽  
Dharamsheela Thakur ◽  
Nitish Kumar ◽  
Tribhuwan Kumar ◽  
...  

2013 ◽  
pp. 401-419 ◽  
Author(s):  
Zahid Hameed Siddiqui ◽  
Abdul Mujib ◽  
Mahmooduzzafar ◽  
Junaid Aslam ◽  
Khalid Rehman Hakeem ◽  
...  

2013 ◽  
Vol 49 (3) ◽  
pp. 366-372 ◽  
Author(s):  
Bianca Ortiz da Silva ◽  
Ana Claudia F. Amaral ◽  
José Luiz P. Ferreira ◽  
Laura Jane Moreira Santiago ◽  
Ricardo P. Louro

Author(s):  
Christoph Wawrosch ◽  
Sergey B. Zotchev

AbstractMedicinal plants have been used by mankind since ancient times, and many bioactive plant secondary metabolites are applied nowadays both directly as drugs, and as raw materials for semi-synthetic modifications. However, the structural complexity often thwarts cost-efficient chemical synthesis, and the usually low content in the native plant necessitates the processing of large amounts of field-cultivated raw material. The biotechnological manufacturing of such compounds offers a number of advantages like predictable, stable, and year-round sustainable production, scalability, and easier extraction and purification. Plant cell and tissue culture represents one possible alternative to the extraction of phytochemicals from plant material. Although a broad commercialization of such processes has not yet occurred, ongoing research indicates that plant in vitro systems such as cell suspension cultures, organ cultures, and transgenic hairy roots hold a promising potential as sources for bioactive compounds. Progress in the areas of biosynthetic pathway elucidation and genetic manipulation has expanded the possibilities to utilize plant metabolic engineering and heterologous production in microorganisms. This review aims to summarize recent advances in the in vitro production of high-value plant secondary metabolites of medicinal importance.Key points• Bioactive plant secondary metabolites are important for current and future use in medicine• In vitro production is a sustainable alternative to extraction from plants or costly chemical synthesis• Current research addresses plant cell and tissue culture, metabolic engineering, and heterologous production Graphical abstract


2019 ◽  
Vol 37 (2) ◽  
pp. 124-132 ◽  
Author(s):  
Jean Carlos Cardoso ◽  
Maria Eduarda BS de Oliveira ◽  
Fernanda de CI Cardoso

ABSTRACT The production of secondary metabolites from medicinal plants, also called Plant-Derived Medicinal Compounds (PDMC), is gaining ground in the last decade. Concomitant to the increase in the knowledge about pharmacological properties of these compounds, horticultural plants are becoming the most important, sustainable and low-cost biomass source to obtain high-complex PDMCs to be used as medicaments. Biotechnological tools, including plant cell and tissue culture and plant genetic transformation, are increasingly being employed to produce high quality and rare PDMC under in vitro conditions. The proper use of these technologies requires studies in organogenesis to allow for better control of in vitro plant development and, thus, to the production of specific tissues and activation of biochemical routes that result in the biosynthesis of the target PDMCs. Either biotic or abiotic factors, called elicitors, are responsible for triggering the PDMC synthesis. In vitro techniques, when compared to the conventional cultivation of medicinal plants in greenhouse or in the field, have the advantages of (1) producing PDMCs in sterile and controlled environmental conditions, allowing better control of the developmental processes, such as organogenesis, and (2) producing tissues with high PDMC contents, due to the efficient use of different biotic and abiotic elicitors. Nevertheless, the process has many challenges, e.g., the establishment of step-by-step protocols for in vitro biomass and PDMC production, both involving and being affected by many factors. Other limitations are the high costs in opposition to the relatively cheaper alternative of growing medicinal plants conventionally. This paper aims to quickly review the general origin of plant secondary metabolites, the leading techniques and recent advances for PDMC in vitro production, and the challenges around the use of this promising technology.


2008 ◽  
Vol 5 (2) ◽  
pp. 234-242 ◽  
Author(s):  
Patrick Schneider ◽  
Mathias Misiek ◽  
Dirk Hoffmeister

Sign in / Sign up

Export Citation Format

Share Document